AbbVie, Harbour BioMed, Utrecht University and Erasmus Medical Center have entered into a collaboration to develop a novel antibody therapeutic to prevent and treat COVID-19, the pandemic respiratory disease caused by the SARS-CoV-2 virus.

• The collaboration will focus on advancing the fully human, neutralizing antibody 47D11 discovered by Utrecht, Erasmus and Harbour and recently reported in Nature Communications
  • This antibody targets the conserved domain of the spike protein of SARS-CoV-2
• Under the terms, AbbVie will support the three through the preclinical activities, while simultaneously undertaking preparations for later stage preclinical and clinical development work
• AbbVie will receive an option...
  
  
  
  
   

To read the full article log in. To learn more about a subscription click here.